Amended Statement of Changes in Beneficial Ownership (4/a)
March 05 2021 - 4:40PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
CHAN NELSON C |
2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp
[
TWST
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Last)
(First)
(Middle)
C/O TWIST BIOSCIENCE CORPORATION, 681 GATEWAY BLVD. |
3. Date of Earliest Transaction
(MM/DD/YYYY)
2/4/2020 |
(Street)
SOUTH SAN FRANCISCO, CA 94080
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
2/6/2020 |
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Director Stock Option (right to buy) | $26.20 | 2/4/2020 | | A | | 11297 (1) | | (2) | 2/3/2030 | Common Stock | 11297 (1) | $0.00 | 11297 (1) | D | |
Explanation of Responses: |
(1) | The Form 4 originally filed on February 6,2020 incorrectly reported 5,648 options. |
(2) | 100% of the shares subject to the option will vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Issuer's first annual meeting of stockholders following the date of grant, subject to the Reporting Person's continuous service through each vesting date. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
CHAN NELSON C C/O TWIST BIOSCIENCE CORPORATION 681 GATEWAY BLVD. SOUTH SAN FRANCISCO, CA 94080 | X |
|
|
|
Signatures
|
/s/ William Solis, as Attorney-in-Fact | | 3/5/2021 |
**Signature of Reporting Person | Date |
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Aug 2024 to Sep 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Sep 2023 to Sep 2024